Ástralía - enska - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - anidulafungin, quantity: 100 mg - injection, powder for - excipient ingredients: tartaric acid; mannitol; fructose; polysorbate 80 - treatment of invasive candidiasis, including candidaemia in adult and in paediatric patients one month and older (see section 5.1)

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 40 mg/ml - suspension - excipient ingredients: sodium benzoate; liquid glucose; titanium dioxide; polysorbate 80; xanthan gum; purified water; sodium citrate dihydrate; glycerol; simethicone; citric acid monohydrate; flavour - noxafil (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older; invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy; fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole.prophylaxis of invasive fungal infections, among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - micafungin sodium, quantity: 101.73 mg (equivalent: micafungin, qty 100 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide; lactose monohydrate - mycamine is indicated for: ? treatment of invasive candidiasis in children and adults ? treatment of oesophageal candidiasis in adults, adolescents greater than or equal to 16 years of age and the elderly patients for whom intravenous therapy is appropriate ? prophylaxis of candida infection in children and adult patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/?l) for 10 or more days.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

astellas pharma australia pty ltd - micafungin sodium, quantity: 50.86 mg (equivalent: micafungin, qty 50 mg) - injection, powder for - excipient ingredients: citric acid; sodium hydroxide; lactose monohydrate - mycamine is indicated for: ? treatment of invasive candidiasis in children and adults ? treatment of oesophageal candidiasis in adults, adolescents greater than or equal to 16 years of age and the elderly patients for whom intravenous therapy is appropriate ? prophylaxis of candida infection in children and adult patients undergoing allogeneic haematopoietic stem cell transplantation or patients who are expected to have neutropenia (absolute neutrophil count < 500 cells/?l) for 10 or more days.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - ivermectin, quantity: 3 mg - tablet, uncoated - excipient ingredients: microcrystalline cellulose; pregelatinised maize starch; magnesium stearate; butylated hydroxyanisole; citric acid - stromectol (ivermectin) is indicated for the treatment of: a) onchocerciasis and intestinal strongyloidiasis (anguillulosis). b) crusted scabies in conjunction with topical therapy c) human sarcoptic scabies when prior topical treatment has failed or is contraindicated. treatment is only justified when the diagnosis of scabies has been established clinically and /or by parasitological examination. without formal diagnosis, treatment is not justified in case of pruritus alone.?

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

inova pharmaceuticals (australia) pty ltd - flucytosine, quantity: 10 mg/ml - injection, solution - excipient ingredients: sodium chloride; hydrochloric acid; trometamol; water for injections - indications as at 15 march 1996: antocil is indicated in the treatment of generalised candidiasis, cryptococcosis and chromoblastomycosis.

Ísrael - enska - Ministry of Health

padagis israel agencies ltd, israel - clotrimazole - lozenges - clotrimazole 10 mg - clotrimazole - for local treatment of oropharyngeal candidiasis.prophylactic treatment to reduce incidence of oropharyngeal candidiasis in patientsimmunocompromised by:- chemotherapy,- radiotherapy,- steroid therapy in leukemia,- solid tumors,- renal transplantation.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - posaconazole, quantity: 40 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; sodium citrate dihydrate; citric acid monohydrate; titanium dioxide; glycerol; xanthan gum; liquid glucose; peg-40 hydrogenated castor oil; purified water; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; flavour - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: ? treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Evrópusambandið - enska - EMA (European Medicines Agency)

neutec pharma plc - recombinant human monoclonal antibody to hsp - candidiasis - antimycotics for systemic use - treatment of invasive candidiasis in adult patients, in combination with amphotericin b or a lipid formulation of amphotericin b.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - metronidazole, quantity: 200 mg - tablet, uncoated - excipient ingredients: hypromellose; macrogol 400; magnesium stearate; maize starch; povidone; calcium hydrogen phosphate - anaerobic infections: treatment of infections in which anaerobic bacteria have been identified or are suspected as pathogens, particularly bacteroides fragilis and other species of bacteroides, and other species such as fusobacteria, eubacteria, clostridia and anaerobic streptococci. flagyl has been used successfully in septicaemia; bacteraemia; brain abscess; necrotising pneumonia; osteomyelitis; puerperal sepsis; pelvic abscess; pelvic cellulitis; postoperative wound infections. note: metronidazole is inactive against aerobic and facultative anaerobic bacteria. other indications: oral treatment of urogenital trichomoniasis in the female (trichomonal vaginitis) and in the male, and for the treatment of bacterial vaginosis. the male consort of females suffering from urogenital trichomoniasis should be treated concurrently; all forms of amoebiasis (intestinal and extraintestinal disease and that of symptomless cyst passers); giardiasis; acute ulcerative gingivitis.